Matchpoint Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Matchpoint Therapeutics, Inc. - overview
Established
2021
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Founded in 2021 and based in Massachusetts, US, Matchpoint Therapeutics, Inc. is a biotech company that focuses on the development of covalent medicines. Andre Turenne, the company's president and CEO, served as President and Chief Executive Officer of Voyager Therapeutics and Senior Vice President and Global Head of Business Development & Licensing at Sanofi. In 2022, it raised USD 30 million in seed funding co-led by new investors Atlas Venture and Access Industries.
The company's key products include covalent drugs and the advanced covalent exploration (ACE) platform. The advanced covalent exploration (ACE) platform. The advanced covalent exploration (ACE) platform provides services such as pathogenic protein identification and proprietary libraries of covalent compounds.
Current Investors
Atlas Venture, Access Industries, Alexandria Venture Investments
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.matchpointtx.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.